Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | Refining molecular subgroups in pMMR endometrial cancer in DUO-E

Shannon Westin, MD, FASCO, The University of Texas MD Anderson Cancer Center & GOG-F, Houston, TX, comments on the importance of breaking down mismatch repair proficient groups into more specific molecular subgroups in in endometrial cancer, such as HER2 positives and P53 wild types or mutants, to better understand the benefits of combination therapies. Preliminary analyses in the Phase III DUO-E (NCT04269200) trial suggest patients with P53 mutations, BRCA mutations, or homologous recombination repair gene mutations may derive the most benefit from the addition of olaparib. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Unfortunately, when we designed these trials, my trial as well as a lot of the trials that have been published in Upfront and Advanced and Recurrent and Metasternal Cancer, we lumped all mismatch repair proficient together. And we know that’s not right, right? So we need to break out the HER2 positives, the P53 wild types, the P53 mutants. So with that being said, some of the analyses we previously have done with DuoE have indicated that the potential molecular groups that might benefit the most from the addition of Olaparib are those that with a P53 mutation, BRCA mutation, homologous recombination repair gene mutations...

Unfortunately, when we designed these trials, my trial as well as a lot of the trials that have been published in Upfront and Advanced and Recurrent and Metasternal Cancer, we lumped all mismatch repair proficient together. And we know that’s not right, right? So we need to break out the HER2 positives, the P53 wild types, the P53 mutants. So with that being said, some of the analyses we previously have done with DuoE have indicated that the potential molecular groups that might benefit the most from the addition of Olaparib are those that with a P53 mutation, BRCA mutation, homologous recombination repair gene mutations. But all of that’s exploratory. But certainly that’s the population that I think probably benefits the most from the combination therapy.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.